

CLOZAPINE MONITORING: EFFICACY, SAFETY AND THE INFLUENCE OF SMOKING ON PLASMA LEVELS



V. GARCIA ZAFRA, I. CASTEJÓN GRAO, S. MACIA SORIANO, G. MIRALLES ANDREU, D. MARTINEZ-CABALLERO MARTINEZ, A.C. MURCIA LOPEZ. Hospital General Universitario de Elche, Pharmacy Department. farmaelx@gva.es

BACKGROUND AND IMPORTANCE

Monitoring clozapine plasma concentrations is crucial to optimize efficacy and prevent hematological toxicity.

AIM AND OBJECTIVES

To assess the efficacy and safety of clozapine in patients with schizophrenia or psychosis by determining trough plasma concentrations.

Smoking significantly decreases plasma concentrations, potentially compromising treatment effectiveness.

MATHERIAL AND METHODS

Retrospective observational study.
Industry 2023 - September 2024.


S Dose adjustments and acceptance was evaluated.

- Sex
- Weight
- 🚺 Variables 🚽 Age

0

- Diagnosis
- Smoking habits
- Dose
- Trough concentrations (therapeutic range: 250-700ng/mL)
- Hematological parameters (leukopenia, neutropenia, eosinophilia and thrombocytopenia).





Average dose (mg) Average levels (ng/mL) Smokers Non-Smokers 6 patients with mild thrombocytopenia (<150.000/mm³).

CONCLUSION AND RELEVANCE

Some patients benefit from clozapine despite subtherapeutic plasma concentrations.

Smoking significantly reduces clozapine plasma concentrations.

Monitoring plasma levels is essential to ensure treatment safety and efficacy.

